# EDGAR Filing Document

**Accession Number:** 0000793171
**File Stem:** 0001493152-23-004852
**Filing Date:** 2023-2
**Character Count:** 11457
**Document Hash:** e823d8c83bef090cdefd54f3db5529be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-004852.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001493152-23-004852

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vitro Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0000793171
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 841012042
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-41585
- **FILM NUMBER:** 23628835

**BUSINESS ADDRESS:**
- **STREET 1:** 4621 TECHNOLOGY DRIVE
- **CITY:** GOLDEN
- **STATE:** CO
- **ZIP:** 80403
- **BUSINESS PHONE:** (720) 859-4120

**MAIL ADDRESS:**
- **STREET 1:** 4621 TECHNOLOGY DRIVE
- **CITY:** GOLDEN
- **STATE:** CO
- **ZIP:** 80403

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VITRO DIAGNOSTICS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LABTEK INC
- **DATE OF NAME CHANGE:** 19870217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMPERIAL MANAGEMENT INC
- **DATE OF NAME CHANGE:** 19870201
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MUSICK JAMES R
- **CENTRAL INDEX KEY:** 0001168925

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**MAIL ADDRESS:**
- **STREET 1:** 9238 BLACK MOUNTAIN DRIVE
- **CITY:** CONIFER
- **STATE:** CO
- **ZIP:** 80433

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934<br> (Amendment No.)\***

**VITRO BIOPHARMA, INC.**

**(Name of Issuer)**

**Common Stock, par value $0.001 per share<br> (Title of Class of Securities)**

**928501303<br> (CUSIP Number)**

**December 31, 2022<br> (Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 928501303

(1) Names
 of reporting persons James
 R. Musick

(2) Check
 the appropriate box if a member of a group (see instructions) (a)
 ☐ (b) ☐

(3) SEC
 use only

(4) Citizenship
 or place of organization United
 States of America

---

| | |
|:---|:---|
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (5) |
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (6) Shared voting power<br>25,684,484<sup>(1)(2)</sup> |
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (7) Sole dispositive power<br>7,040,498<sup>(1)</sup> |
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (8) Shared dispositive power<br>25,684,484<sup>(1)(2)</sup> |

---

(9) Aggregate
 amount beneficially owned by each reporting person 32,724,982<sup>(1)(2)</sup>

(10) Check
 if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐

(11) Percent
 of class represented by amount in Row (9) 27.3%<sup>(3)</sup>

(12) Type
 of reporting person (see instructions) IN

(1) Includes 4,700,000 shares issuable upon exercise of options held directly by James R. Musick that are exercisable within 60 days of the date of February 13, 2023 (the "Options").

(2) Includes (i) 22,727,635 shares held in the James R. Musick Trust, a grantor trust, of which James R. Musick has sole voting and investment control, and (ii) 2,956,849 shares owned by the reporting person's spouse, of which the reporting person disclaims beneficial ownership

(3) Based on 115,160,180 shares of Common Stock issued and outstanding as of January 27, 2023, in addition to the 4,700,000 shares of common stock issuable upon conversion exercise of the Options, as reported in the Issuer's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on January 30, 2023.

CUSIP No. 928501303

(1) Names
 of reporting persons James
 R. Musick Trust

(2) Check
 the appropriate box if a member of a group (see instructions) (a)
 ☐ (b) ☐

(3) SEC
 use only

(4) Citizenship
 or place of organization Colorado

---

| | | |
|:---|:---|:---|
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (5) | Sole voting power<br>-0- |
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (6) | Shared voting power<br>22,727,635<sup>(1)</sup> |
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (7) | Sole dispositive power<br>-0- |
| Number of<br> shares<br> beneficially<br> owned by<br> each<br> reporting<br> person<br> with: | (8) | Shared dispositive power<br>22,727,635<sup>(1)</sup> |

---

(9) Aggregate
 amount beneficially owned by each reporting person 22,727,635<sup>(1)</sup>

(10) Check
 if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐

(11) Percent
 of class represented by amount in Row (9) 19.7%<sup>(2)</sup>

(12) Type
 of reporting person (see instructions) OO

(1) Includes 22,727,635 shares held in the James R. Musick Trust, a grantor trust, of which James R. Musick serves as the sole trustee.

(2) Based on 115,160,180 shares of Common Stock issued and outstanding as of January 27, 2023, as reported in the Issuer's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on January 30, 2023.

---

| | |
|:---|:---|
| **Item 1(a)** | **Name of issuer:** |

---

Vitro BioPharma, Inc. (the "Issuer").

---

| | |
|:---|:---|
| **Item 1(b)** | **Address of issuer's principal executive offices** |

---

3200 Cherry Creek Drive South, Suite 720

Denver, Colorado 80209

---

| | |
|:---|:---|
| Item 2(a) | Name of person filing: |

---

James R. Musick

James R. Musick Trust (the "Trust")

---

| | |
|:---|:---|
| **Item 2(b)** | **Address of principal business office or, if none, residence:** |

---

The principal business address of each of James R Musick and the James R. Musick Trust is as follows:

c/o Vitro BioPharma, Inc.

3200 Cherry Creek Drive South, Suite 720

Denver, Colorado 80209

---

| | |
|:---|:---|
| **Item 2(c)** | **Citizenship:** |

---

James R. Musick – United States of America

James R. Musick Trust – Organized and administered in the State of Colorado

---

| | |
|:---|:---|
| **Item 2(d)** | **Title of class of securities:** |

---

Common Stock, par value $0.001 per share

---

| | |
|:---|:---|
| **Item 2(e)** | **CUSIP No.:** |

---

928501303

**Item 3.** **If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable.

**Item 4.** **Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) As of December 31, 2022, the reporting persons may be deemed to directly or indirectly beneficially own an aggregate total of 32,724,982 shares of the Issuer's Common Stock.

As of that date, Dr. Musick is deemed to be the beneficial owner of 32,724,982, consisting of: (i) 2,340,498 owned directly by him, (ii) 4,700,000 shares of Common Stock which may be issued upon exercise of the Options described on the Cover Page, (iii) 2,956,849 shares of Common Stock owned by the reporting person's spouse, and (iv) 22,727,635 shares of Common Stock owned by the Trust, of which the reporting person is the sole trustee and has sole voting and investment control.

As of December 31, 2022, the Trust is deemed to be the beneficial owner of 22,727,635 shares of Common Stock.

(b) Percent of class: See the responses in Row 11 on the attached Cover Pages.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: See the responses in Row 5 on the attached Cover Pages.

(ii) Shared power to vote or to direct the vote: See the responses in Row 6 on the attached Cover Pages.

(iii) Sole power to dispose or to direct the disposition of: See the responses in Row 7 on the attached Cover Pages.

(iv) Shared power to dispose or to direct the disposition of: See the responses in Row 8 on the attached Cover Pages.

The percentages used herein and in this Item 4 are calculated based on 115,160,180 shares of Common Stock issued and outstanding as of January 27, 2023, in addition to, with respect to the holdings of James R. Musick, the 4,700,000 shares of common stock issuable upon conversion exercise of the Options, as reported in the Issuer's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on January 30, 2023.

---

| | |
|:---|:---|
| ***Item 5.*** | ***Ownership of 5 Percent or Less of a Class.*** |

---

 ****

Not applicable.

**Item 6.** **Ownership of More than 5 Percent on Behalf of Another Person.**

Not applicable.

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable.

**Item 8.** **Identification and Classification of Members of the Group.**

Not applicable.

**Item 9.** **Notice of Dissolution of Group.**

Not applicable.

**Item 10.** **Certifications**

Not applicable.

**Signatures**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

---

| | |
|:---|:---|
| **JAMES R. MUSICK** | **JAMES R. MUSICK** |
| */s/ James R. Musick* | */s/ James R. Musick* |
| **JAMES R. MUSICK TRUST** | **JAMES R. MUSICK TRUST** |
| By: | */s/ James R. Musick* |
| Name: | James R. Musick |
| Title: | Trustee |

---

**INDEX TO EXHIBITS**

Exhibit 99.1 [Joint Filing Agreement](ex99-1.htm)

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock of Vitro BioPharma, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

Dated: February 14, 2023

---

| | |
|:---|:---|
| **JAMES R. MUSICK** | **JAMES R. MUSICK** |
| */s/ James R. Musick* | */s/ James R. Musick* |
| **JAMES R. MUSICK TRUST** | **JAMES R. MUSICK TRUST** |
| By: | */s/ James R. Musick* |
| Name: | James R. Musick |
| Title: | Trustee |

---